Low-voltage online stimulated microextraction of Glibenclamide (cas 10238-21-8) from whole blood
-
Add time:07/27/2019 Source:sciencedirect.com
In the present study, Glibenclamide (cas 10238-21-8) (GLI) was determined in blood samples through the application of a method based on coupling low-voltage electromembrane extraction (LV-EME) and fast Fourier transform square wave voltammetry (FFTSWV). The parameters influencing the LV-EME of GLI (i.e. extraction time, electrical potential and pH of donor phases) were optimized using a central composite design (CCD) and the optimal values of the important parameters for the LV-EME-FFTSWV were obtained to be (frequency = 1420 Hz/amplitude = 20 mV, extraction time = 30 min, applied voltage = 5 V, supported liquid membrane (SLM) = 1-octanol, pH values of the feed and receive sources = 8.0 and 7.0). Under these conditions, GLI was extracted from blood samples with a recovery percentage of 26. The LV-EME-FFTSWV method was found to have linear responses over two wide concentration ranges of 10–1000 and 1000–10,000 ng/mL and determination coefficients of 0.997 and 0.994, respectively. The limits of detection and quantification of 3 ng/mL and 10 ng/mL and also the intra- and inter-day precisions of 3.8% and 5.1% were determined.
We also recommend Trading Suppliers and Manufacturers of Glibenclamide (cas 10238-21-8). Pls Click Website Link as below: cas 10238-21-8 suppliers
Prev:Neuroprotective potential of Glibenclamide (cas 10238-21-8) is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage
Next:Peceosomes for oral delivery of Glibenclamide (cas 10238-21-8): In vitro in situ correlation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Characterization and evaluation of different mesoporous silica kinds as carriers for the development of effective oral dosage forms of Glibenclamide (cas 10238-21-8)07/31/2019
- Controlled release of Glibenclamide (cas 10238-21-8) from monolithic silica subdermal implants produced by the sol-gel process and its use for hyperglycaemia treatment in a murine model07/30/2019
- Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a Glibenclamide (cas 10238-21-8)-induced canine hypoglycaemia model07/29/2019
- Peceosomes for oral delivery of Glibenclamide (cas 10238-21-8): In vitro in situ correlation07/28/2019
- Neuroprotective potential of Glibenclamide (cas 10238-21-8) is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage07/26/2019
- Role of AKR1C3 in renal injury and Glibenclamide (cas 10238-21-8) is anti-inflammatory in preeclamptic rats07/25/2019
- Electrochemical detection of gliclazide and Glibenclamide (cas 10238-21-8) on ZnIn2S4 nanoparticles-modified carbon ionic liquid electrode07/24/2019
- Studying tautomerism in an important pharmaceutical Glibenclamide (cas 10238-21-8) confined in the thin nanometric layers07/23/2019